30-Second Takeaway
- Cover all residual disease when delivering consolidative RT for extensive-stage SCLC; partial coverage loses substantial survival benefit.
- Online adaptive RT improves target coverage and organ sparing but remains resource-intensive, awaiting phase II–III outcome data.
- For breast cancer brain metastases, stereotactic RT is associated with better survival than WBRT, yet access remains inequitable.
- Blood-dose–based and radiomics-driven models are emerging to individualize risk of lymphopenia and radiation pneumonitis.
- AI imaging tools may refine targets in CNS tumors, while novel immunomodulators could radiosensitize glioblastoma in the future.
Week ending April 25, 2026
Target selection, adaptation, and toxicity prediction in modern radiation oncology
Complete consolidative RT improves survival in extensive-stage SCLC
In this 70-patient ES-SCLC cohort, consolidative RT to all radiographically targetable residual disease improved OS and PFS versus incomplete consolidation. Adjusted restricted mean OS gain with complete consolidation was 6.47 months at 36 months; PFS gain was 4.63 months. Among oligometastatic patients, complete consolidation further improved OS and short-term PFS, but oligometastatic status alone was not independently prognostic. These data argue for encompassing all residual disease in consolidative fields when technically feasible after first-line systemic therapy.
Online adaptive RT offers dosimetric gains but needs proof of outcome benefit
This review reports that MR- and CT-guided online adaptive RT consistently improves target coverage and reduces OAR doses across multiple tumor sites. Early clinical signals include better gastrointestinal tolerance in pancreatic SBRT and improved genitourinary outcomes in prostate cancer. Implementation is hampered by long on-couch times, complex workflows, and substantial staffing and training demands. AI-based autosegmentation and optimization may streamline processes, but large prospective trials are still needed to confirm survival and toxicity benefits.
SRT use and survival in breast cancer brain metastases show disparities
Among 8,909 breast cancer patients with brain metastases, 43.4% received brain RT, mostly WBRT (74.1%) versus SRT (25.9%). In multivariable, weighted analysis, SRT was associated with better OS than WBRT among RT recipients (HR 0.76). Systemic therapy, with or without RT, improved OS, whereas RT alone did not significantly improve survival. African American, lower-income, urban, triple-negative patients, and those at community facilities were more likely to receive WBRT rather than SRT. These patterns highlight both a survival association with SRT and substantial inequities in access to stereotactic techniques.
Modality-specific blood-dose NTCP models for lymphopenia in lung RT
This study developed blood-dose–based NTCP models for severe radiation-induced lymphopenia in 131 lung cancer patients treated with IMRT or IMPT. Severe lymphopenia incidence was higher with IMRT than IMPT (61.7% vs 32.4%), reflecting differing blood dose distributions. Blood generalized equivalent uniform dose independently predicted severe lymphopenia in IMRT patients, with strong model discrimination (AUC 0.82). Separate IMRT and IMPT models performed well in their own cohorts, but the IMRT model overestimated risk when applied to IMPT cases. These findings support using modality-specific NTCP modeling when comparing photon versus proton plans for lymphopenia risk.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.